David B Schmick is a pharmacist who is specialized in Oncology in Spokane Valley, Washington. Patients can reach him at 5105 E 3rd Ave, Spokane Valley or contact him on 509-228-1313. Active license number of David B Schmick is PL00014325 for Oncology in Washington. David B Schmick is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
David B Schmick speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
David B Schmick
Specialization:
Oncology
Gender:
Male
Location:
5105 E 3rd Ave, Spokane Valley, Washington, 99212-0725
Phone:
509-228-1313
Fax:
509-535-4290
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of David B Schmick are as mentioned below.
NPI Number:
1205984671
NPI Enumeration Date:
08 Jan, 2007
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for David B Schmick are as mentioned below.
Specialization
License Number
State
Status
Oncology
PL00014325
Washington
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
5105 E 3rd Ave, Spokane Valley, Washington
Zip:
99212-0725
Phone Number:
509-228-1313
Fax Number:
509-535-4290
Patients can reach David B Schmick at 5105 E 3rd Ave, Spokane Valley, Washington or can call on phone at 509-228-1313.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 May, 2024.